

**FAES FARMA, S.A. ANNOUNCES THE ACQUISITION OF  
GLOBAL FARMA, S.A., EXPANDING ITS OPERATIONS IN  
CENTRAL AMERICA & THE CARIBBEAN**

**Leioa, Spain – March 08, 2021** - Faes Farma, S.A., today signed a purchase contract by which it acquires 100% of the shares of Global Farma, S.A., a company worth 30 million US dollars (USD).

The operation has been fully financed with Faes Farma Group's own resources. The initial payment as agreed in the contract has been executed in cash. The full completion of the operation is only dependent on the receipt of the funds by the selling party.

Global Farma, S.A., is headquartered in Guatemala, although it operates commercially throughout the Central American - Dominican region. The pharmaceutical market in this region is worth approximately 2,500 million euros, exceeding the value of the Portuguese market and approximately 25% of the value of the Spanish market. It is the fourth largest pharmaceutical market in Latin America after Brazil, Mexico and Argentina.

In 2020, Global Farma, S.A. sales amounted to USD 21 million with an EBITDA of USD 5.6 million.

Global Farma, S.A., reached the 54th position in the Central America - Dominican region (data: IQVIA December 2020). Almost half of its sales took place in Guatemala, where the laboratory occupies the 25th position (data: IQVIA December 2020).

Global Farma, S.A., mainly markets its own brand prescription products, in the cardiovascular, anti-infective and digestive / metabolism areas, which are promoted through medical visits, mainly in the private sector.

This acquisition adds value to Faes Farma, S.A., in several aspects:

- a) A strong commercial platform throughout the Central America - Caribbean region that will allow to reinforce the promotion of the existing Faes Farma portfolio, (including Bilastine and Calcifediol) with a 2020 sales value of more than 6 million US dollars (data: IQVIA) in this region.
- b) An industrial plant for solids, liquids and injectables.
- c) An efficient development unit for new branded products that helps the Faes Farma Group's portfolio to expand in Latin America and Africa.

By adding this acquisition in Central America - Caribbean to its current sales, Faes Farma, S.A., will reach the 44th position in this market.

The acquisition is fully in line with the strategic initiatives of the Group, strengthening its presence in Latin America, which is the 2<sup>nd</sup> biggest direct commercial area (with its own sales network) after Iberia, while serving other regions indirectly through licenses and exports.